Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.123385 ↗Abstract
BACKGROUND Sorafenib and lenvatinib remain the standard first-line therapies for unresectable hepatocellular carcinoma (HCC); however, disease progression is nearly universal. Regorafenib has become a standard second-line agent based on the RESORCE trial. Immune checkpoint inhibitor (ICI), particularly programmed cell death-1 (PD-1) inhibitors, have further reshaped the therapeutic landscape. Preclinical studies have demonstrated that regorafenib may modulate the tumor immune microenvironment, thereby enhancing antitumor immunity. Nevertheless, robust real-world evidence evaluating the efficacy of regorafenib combined with PD-1 inhibitors after first-line failure remains limited. AIM To compare the clinical efficacy of regorafenib plus PD1 inhibitor vs monotherapy as a second-line treatment for patients with unresectable HCC. METHODS This study analyzed 140 advanced HCC patients who experienced disease progression after first-line therapy between February 2019 and August 2024. Patients were divided into two cohorts, the regorafenib plus PD1 inhibitor group [regorafenib plus PD1 inhibitor (RP) group, n = 101] and the regorafenib monotherapy group [regorafenib monotherapy (R) group, n = 39]. Clinical outcomes were evaluated using objective response rate, disease control rate (DCR), progression-free survival, and overall survival (OS). Subgroup analyses and multivariate Cox regression analysis were performed to identify prognostic factors. RESULTS The RP group achieved a higher DCR, with better control of both intrahepatic and extrahepatic lesions than the R group. Median PFS (5.4 months vs 2.7 months, P = 0.003) and OS (54.8 months vs 25.3 months, P = 0.041) were longer in the RP group. Patients with prior ICI exposure achieved longer OS with RP therapy (P = 0.006), whereas no significant OS difference was observed in ICI-naive patients. First-line treatment type (lenvatinib vs sorafenib) did not affect second-line outcomes. Multivariable analysis identified second-line PD-1 inhibitor therapy as an independent predictor of PFS, whereas no independent predictors of OS were identified. CONCLUSION For patients with unresectable HCC who fail first-line treatment, the combination of regorafenib and PD-1 inhibitors confers better survival benefits and disease control than regorafenib monotherapy.
EUVIMED